blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2174666

EP2174666 - MEDICINAL AGENT FOR TREATMENT OF AMYLOID BETA-INDUCED CEREBRAL CIRCULATION OR CEREBRAL BLOOD FLOW DISORDERS [Right-click to bookmark this link]
Former [2010/15]MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE
[2013/31]
StatusNo opposition filed within time limit
Status updated on  24.10.2014
Database last updated on 12.10.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): TR		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
Daiichi Sankyo Company, Limited
3-5-1, Nihonbashi Honcho Chuo-ku
Tokyo 103-8426 / JP
For all designated states
Osaka University
1-1, Yamadaoka Suita-shi
Osaka 565-0871 / JP
[2010/15]
Inventor(s)01 / MORISHITA, Ryuichi
c/o OSAKA UNIVERSITY
1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
02 / SATO, Naoyuki
c/o OSAKA UNIVERSITY
1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
03 / TAKEDA, Shuko
c/o OSAKA UNIVERSITY
1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
 [2013/51]
Former [2010/15]01 / MORISHITA, Ryuichi
c/o OSAKA UNIVERSITY 1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
02 / SATO, Naoyuki
c/o OSAKA UNIVERSITY 1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
03 / TAKEDA, Shuko
c/o OSAKA UNIVERSITY 1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
Representative(s)Wallace, Sheila Jane, et al
Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[N/P]
Former [2010/15]Wallace, Sheila Jane, et al
Marks & Clerk LLP 90 Long Acre London
WC2E 9RA / GB
Application number, filing date08765314.309.06.2008
[2010/15]
WO2008JP60513
Priority number, dateJP2007016507122.06.2007         Original published format: JP 2007165071
[2010/15]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009001661
Date:31.12.2008
Language:JA
[2009/01]
Type: A1 Application with search report 
No.:EP2174666
Date:14.04.2010
Language:EN
[2010/15]
Type: B1 Patent specification 
No.:EP2174666
Date:18.12.2013
Language:EN
[2013/51]
Search report(s)International search report - published on:JP31.12.2008
(Supplementary) European search report - dispatched on:EP22.06.2010
ClassificationIPC:A61K31/41, A61K31/4178, A61K31/4184, A61K31/454, A61P25/28, A61P43/00
[2010/29]
CPC:
A61K31/41 (EP,US); A61K31/4178 (EP,US); A61K31/4184 (EP,US);
A61K31/454 (EP,US); A61P25/28 (EP); A61P43/00 (EP);
A61P7/00 (EP) (-)
Former IPC [2010/15]A61K45/00, A61K31/41, A61K31/4178, A61K31/4184, A61K31/454, A61P25/28, A61P43/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/15]
TitleGerman:MEDIZINISCHES MITTEL ZUR BEHANDLUNG VON AMYLOID BETA-INDUZIERTEN STÖRUNGEN DER CEREBRALEN ZIRKULATION ODER DES CEREBRALEN BLUTFLUSSES[2013/32]
English:MEDICINAL AGENT FOR TREATMENT OF AMYLOID BETA-INDUCED CEREBRAL CIRCULATION OR CEREBRAL BLOOD FLOW DISORDERS[2013/32]
French:AGENT MÉDICAMENTEUX POUR LE TRAITEMENT DE TROUBLES DE LA CIRCULATION CÉRÉBRALE OU DU FLUX SANGUIN CÉRÉBRAL INDUITS PAR L'AMYLOÏDE BÊTA[2013/32]
Former [2010/15]MEDIZINISCHES MITTEL ZUR PRÄVENTION ODER BEHANDLUNG VON ALZHEIMER-KRANKHEIT
Former [2010/15]MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE
Former [2010/15]AGENT MÉDICAMENTEUX POUR LA PRÉVENTION OU LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
Entry into regional phase22.01.2010Translation filed 
22.01.2010National basic fee paid 
22.01.2010Search fee paid 
22.01.2010Designation fee(s) paid 
22.01.2010Examination fee paid 
Examination procedure22.01.2010Examination requested  [2010/15]
08.12.2010Amendment by applicant (claims and/or description)
02.02.2011Despatch of a communication from the examining division (Time limit: M04)
06.06.2011Reply to a communication from the examining division
29.09.2011Despatch of a communication from the examining division (Time limit: M02)
06.12.2011Reply to a communication from the examining division
02.05.2012Despatch of a communication from the examining division (Time limit: M02)
22.06.2012Reply to a communication from the examining division
10.07.2013Communication of intention to grant the patent
08.11.2013Fee for grant paid
08.11.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.02.2011
Opposition(s)19.09.2014No opposition filed within time limit [2014/48]
Fees paidRenewal fee
11.06.2010Renewal fee patent year 03
13.06.2011Renewal fee patent year 04
14.06.2012Renewal fee patent year 05
10.06.2013Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.06.2008
AT18.12.2013
BE18.12.2013
BG18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
MT18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
TR18.12.2013
NO18.03.2014
GR19.03.2014
IS18.04.2014
PT18.04.2014
IE09.06.2014
LU09.06.2014
CH30.06.2014
LI30.06.2014
[2016/33]
Former [2016/32]HU09.06.2008
AT18.12.2013
BE18.12.2013
BG18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
MT18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
NO18.03.2014
GR19.03.2014
IS18.04.2014
PT18.04.2014
IE09.06.2014
LU09.06.2014
CH30.06.2014
LI30.06.2014
Former [2016/28]AT18.12.2013
BE18.12.2013
BG18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
MT18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
NO18.03.2014
GR19.03.2014
IS18.04.2014
PT18.04.2014
IE09.06.2014
LU09.06.2014
CH30.06.2014
LI30.06.2014
Former [2016/25]AT18.12.2013
BE18.12.2013
BG18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
MT18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
IE09.06.2014
LU09.06.2014
CH30.06.2014
LI30.06.2014
Former [2016/16]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
MT18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
IE09.06.2014
LU09.06.2014
CH30.06.2014
LI30.06.2014
Former [2015/24]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
IE09.06.2014
LU09.06.2014
CH30.06.2014
LI30.06.2014
Former [2015/21]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
IE09.06.2014
LU09.06.2014
CH30.06.2014
LI30.06.2014
Former [2015/20]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
LU09.06.2014
CH30.06.2014
LI30.06.2014
Former [2015/09]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
LU09.06.2014
Former [2014/48]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
Former [2014/39]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
Former [2014/37]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
PL18.12.2013
RO18.12.2013
SE18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
Former [2014/36]BE18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
SE18.12.2013
NO18.03.2014
IS18.04.2014
Former [2014/34]BE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
SE18.12.2013
NO18.03.2014
Former [2014/25]FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
SE18.12.2013
NO18.03.2014
Former [2014/23]FI18.12.2013
HR18.12.2013
LT18.12.2013
SE18.12.2013
NO18.03.2014
Former [2014/22]FI18.12.2013
LT18.12.2013
SE18.12.2013
NO18.03.2014
Former [2014/20]LT18.12.2013
NO18.03.2014
Documents cited:Search[X]  - KEHOE ET AL, "Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB LNKD- DOI:10.1016/S1474-4422(07)70077-7, (20070401), vol. 6, no. 4, ISSN 1474-4422, pages 373 - 378, XP005931881 [X] 1,3,19,21,23,25 * abstract; proprietor 377, left-hand column 2nd full paragraph *

DOI:   http://dx.doi.org/10.1016/S1474-4422(07)70077-7
International search[X]JPH0578328  (SANKYO CO);
 [XP]WO2007112288  (SINAI SCHOOL MEDICINE [US], et al);
 [X]  - TSUKUDA K. ET AL., "Koshokuen.Koshiboshoku Fuka de Mitomerareta Ninchi Kino no Teika ni Taisuru Olmesartan to Azelnidipine no Koka", JAPANESE JOURNAL OF GERIATRICS, (20070520), vol. 44, page 129, XP008127986

DOI:   http://dx.doi.org/10.1161/01.ATV.0000205849.22807.6e
 [X]  - GARD P.R., "Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression", EXPERT OPIN. THER. TARGETS, (2004), vol. 8, no. 1, pages 7 - 14, XP009078785
 [X]  - ROSENDORFF C., "Certain anti-hypertensive agents reduce beta-amyloid neuropathology and improve cognition in a mouse model of Alzheimer's disease", CIRCULATION, (2006), vol. 114, no. 18, page 129, XP008128003
 [X]  - TRENKWALDER P., "Potential for antihypertensive treatment with an AT(1)-receptor blocker to reduce dementia in the elderly", J. HUM. HYPERTENS., (2002), vol. 16, no. SUPPL. 3, pages S71 - S75, XP008128004

DOI:   http://dx.doi.org/10.1038/SJ.JHH.1001443
 [X]  - IWAI M. ET AL., "The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage", J. HYPERTENS., (2006), vol. 24, no. 10, pages 2023 - 2031, XP008128005
 [X]  - HOSOMI N. ET AL., "Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia", NEUROSCIENCE, (2005), vol. 134, no. 1, pages 225 - 231, XP004971926

DOI:   http://dx.doi.org/10.1016/j.neuroscience.2005.03.054
 [X]  - GIROUARD H. ET AL., "Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals", ARTERIOSCLER. THROMB. VASC. BIOL., (2006), vol. 26, no. 4, pages 826 - 832, XP008128002

DOI:   http://dx.doi.org/10.1161/01.ATV.0000205849.22807.6e
 [XP]  - MOGI M. ET AL., "Inhibition of cognitive decline in mice fed ad high-salt and cholesterol diet by the angiotensin receptor blockade, olmesartan", NEUROPHARMACOLOGY, (2007), vol. 53, no. 8, pages 899 - 905, XP022358182

DOI:   http://dx.doi.org/10.1016/j.neuropharm.2007.08.020
 [XP]  - WANG J. ET AL., "Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease", J. CLIN. INVEST., (2007), vol. 117, no. 11, pages 3393 - 3402, XP002589379

DOI:   http://dx.doi.org/10.1172/JC131547
by applicant   - KANA TSUKUDA; MASAKI MOGI; MASARU IWAI; MASATSUGU HORIUCHI, DEPARTMENT OF MOLECULAR CARDIOVASCULAR BIOLOGY AND PHARMACOLOGY
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.